Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tirzepatide in Pediatric Participants 6 to Less Than 12 Years of Age With Obesity
NCT07817875Phase 3Recruiting
- Sponsor
- Eli Lilly and Company
- Start
- Sep 2026
- Primary completion
- Dec 2029
- Countries
- 10
01
Overview
Phase 3, randomised, double-blind trial in obesity comparing Tirzepatide with Placebo (2 arms). Primary endpoint: Percent Change from Baseline in Body Mass Index at 84 weeks. Started Sep 2026; status: recruiting.
02
Drugs
03
Conditions
obesity
Beyond the preview
Go deeper on NCT07817875.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07817875.